Nishiwaki, Hiroki
Hasegawa, Takeshi
Shinji, Megumi
Matsuo, Fujio
Watanabe, Tsuyoshi
Makino, Hirofumi
Koiwa, Fumihiko
Hishida, Akira
Article History
Received: 19 November 2017
Accepted: 7 March 2018
First Online: 19 March 2018
Compliance with ethical standards
:
: The CKD-JAC study was supported by research funds with no restriction on publication from Kyowa Hakko Kirin Co., Ltd. Grants received: Hiroki Nishiwaki (Kyowa Hakko Kirin), Tsuyoshi Watanabe(Kyowa Hakko Kirin). Consultancies: Takeshi Hasegawa (Kyowa Hakko Kirin). Honoraria: Takeshi Hasegawa (Kyowa Hakko Kirin, Baxter, Pfizer, Takeda and Novartis), Hirofumi Makino (Kyowa Hakko Kirin). Employment: Megumi Shinji and Fujio Matsuo (Statistical analyses provided by statisticians M.S. and F.M. from Statcom Company were funded by KHK Pharmaceuticals.)
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB Approval Number 2,007,578 in Showa University Fujigaoka Hospital) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.